JP2024521701A5 - - Google Patents
Info
- Publication number
- JP2024521701A5 JP2024521701A5 JP2023571779A JP2023571779A JP2024521701A5 JP 2024521701 A5 JP2024521701 A5 JP 2024521701A5 JP 2023571779 A JP2023571779 A JP 2023571779A JP 2023571779 A JP2023571779 A JP 2023571779A JP 2024521701 A5 JP2024521701 A5 JP 2024521701A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- heavy chain
- antigen
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021095111 | 2021-05-21 | ||
| CNPCT/CN2021/095111 | 2021-05-21 | ||
| CNPCT/CN2022/085622 | 2022-04-07 | ||
| CN2022085622 | 2022-04-07 | ||
| PCT/CN2022/093564 WO2022242679A1 (en) | 2021-05-21 | 2022-05-18 | Anti-cd137 antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521701A JP2024521701A (ja) | 2024-06-04 |
| JP2024521701A5 true JP2024521701A5 (https=) | 2025-05-22 |
Family
ID=84140250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571779A Pending JP2024521701A (ja) | 2021-05-21 | 2022-05-18 | 抗ｃｄ１３７抗体及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240209106A1 (https=) |
| EP (1) | EP4341293A4 (https=) |
| JP (1) | JP2024521701A (https=) |
| CN (1) | CN117355540A (https=) |
| TW (1) | TW202306984A (https=) |
| WO (1) | WO2022242679A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240133746A (ko) * | 2022-01-09 | 2024-09-04 | 아이-맵 바이오파마 컴파니 리미티드 | 다중특이적 작제물 및 이의 용도 |
| JP2026507127A (ja) | 2023-02-28 | 2026-02-27 | ラノバ メディシンズ リミテッド | Ｃｅａｃａｍ５依存性４－１ｂｂアゴニスト性二重特異性抗体 |
| TW202504921A (zh) * | 2023-02-28 | 2025-02-01 | 中國大陸商禮新醫藥科技（上海）有限公司 | Ceacam5依賴性4-1bb促效性雙特異性抗體 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| SG11202000198QA (en) * | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| EP3470428A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting cd137 and methods of use thereof |
| CN109651507B (zh) * | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| EP3710478A1 (en) * | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| CN110003332B (zh) * | 2018-01-05 | 2021-05-11 | 上海原能细胞医学技术有限公司 | Cd137抗体及其应用 |
| WO2019199896A1 (en) * | 2018-04-09 | 2019-10-17 | Compass Therapeutics Llc | Agonist antibodies against human cd137 in cancer that express mhc i |
| EP3827019A1 (en) * | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3636320A1 (en) * | 2018-10-09 | 2020-04-15 | Numab Therapeutics AG | Antibodies targeting cd137 and methods of use thereof |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
-
2022
- 2022-05-18 TW TW111118553A patent/TW202306984A/zh unknown
- 2022-05-18 CN CN202280036534.2A patent/CN117355540A/zh active Pending
- 2022-05-18 WO PCT/CN2022/093564 patent/WO2022242679A1/en not_active Ceased
- 2022-05-18 JP JP2023571779A patent/JP2024521701A/ja active Pending
- 2022-05-18 EP EP22803999.6A patent/EP4341293A4/en active Pending
-
2023
- 2023-11-17 US US18/513,169 patent/US20240209106A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515318A5 (https=) | ||
| JP2022058345A5 (https=) | ||
| JP2024521701A5 (https=) | ||
| KR100221897B1 (ko) | 사람항체의 합성 유전자 뱅크 및 이의 제조방법 | |
| JP2021534762A5 (https=) | ||
| JP2021514664A5 (https=) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| CN101516394B (zh) | 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途 | |
| JP2021525546A5 (https=) | ||
| JP2023516004A5 (https=) | ||
| JP2022514693A5 (https=) | ||
| JP2021511811A5 (https=) | ||
| JP2024531409A5 (https=) | ||
| JP2023539501A5 (https=) | ||
| JP2017506067A5 (https=) | ||
| CN113302207A (zh) | Cd38和icam1抗体及其用途 | |
| JP2013520984A5 (https=) | ||
| JP2022529154A5 (https=) | ||
| JP2010509931A5 (https=) | ||
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| JP2024540148A5 (https=) | ||
| JP2023543493A5 (https=) | ||
| JP2022532991A5 (https=) | ||
| FI4200018T3 (fi) | Anti-par-2-vasta-aineet ja niiden käyttömenetelmät | |
| JP2024516098A5 (https=) |